Psc833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1131-1136

  Bark, H ^a   Choi, Cheol Hee ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

AP 1; C Jun; JNK; Multidrug resistance; Nf b; P glycoprotein; PSC833

Indexed keywords

CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN C JUN; RHODAMINE 123; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; VALSPODAR; ABCB1 PROTEIN, HUMAN; I KAPPA B KINASE; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG ACCUMULATION; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; CELL NUCLEUS; CELL SURVIVAL; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CYCLOSPORINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OLIGONUCLEOTIDES; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA;

EID: 77951890193     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1121-7     Document Type: Article

References (32)

1. Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18:6910-6924
2. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90-97
3. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoproteinmediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233
4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389
5. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
6. Dunn C, Wiltshire C, MacLaren A, Gillespie DA (2002) Molecular mechanism and biological functions of c-Jun. N-terminal kinase signalling via the c-Jun. transcription factor. Cell Signal 14:585-593
7. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171
8. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : a trial of the Eastern Cooperative Oncology Group. Cancer 106:830-838
9. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl):S81-S96
10. Herzog CE, Tsokos M, Bates SE, Fojo AT (1993) Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268:2946-2952
11. Jonsson B, Nilsson K, Nygren P, Larsson R (1992) SDZ PSC-833-a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs 3:641-646
12. Kaminska B, Pyrzynska B, Ciechomska I, Wisniewska M (2000) Modulation of the composition of AP-1 complex and its impact on transcriptional activity. Acta Neurobiol Exp (Wars) 60:395-402
13. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221-227
14. Kim SH, Lee S, Suk K, Bark H, Jun. CD, Kim DK, Choi CH, Yoshimura T (2007) Discoidin domain receptor 1 mediates collagen-induced nitric oxide production in J774A.1 murine macrophages. Free Radic Biol Med 42:343-352
15. Kriehuber E, Bauer W, Charbonnier AS, Winter D, Amatschek S, Tamandl D, Schweifer N, Stingl G, Maurer D (2005) Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood 106:175-183
16. Kruger NJ (1994) The Bradford method for protein quantitation. Methods Mol Biol 32:9-15
17. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K (1998) Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 89:1220-1228
18. Liu M, Li D, Aneja R, Joshi HC, Xie S, Zhang C, Zhou J (2007) PO (2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun. NH2-terminal kinase pathway. J Biol Chem 282:17581-17586
19. Luque I, Gelinas C (1997) Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol 8:103-111
20. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563
21. Miao ZH, Ding J (2003) Transcription factor c-Jun. activation represses mdr-1 gene expression. Cancer Res 63:4527-4532
22. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24
23. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T (1985) Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 82:6133-6137
24. Nakano H (2005) Signaling crosstalk between NF-kappaB and JNK. Seikagaku 77:29-32
25. Pieters R, Huismans DR, Leyva A, Veerman AJ (1988) Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41:323-332
26. Riordan JR, Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254:12701-12705 (Pubitemid 10137661)
27. Shtil AA, Azare J (2005) Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol 246:1-29
28. Thevenod F, Friedmann JM, Katsen AD, Hauser IA (2000) Upregulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium-and reactive oxygen species-induced apoptosis. J Biol Chem 275:1887-1896
29. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354
30. Twentyman PR, Fox NE, White DJ (1987) Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 56:55-57
31. Zhang Y, Chen F (2004) Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun. NH (2)-terminal kinase (JNK). Cancer Res 64:1902-1905
32. Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC (2006) Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun. NH2-terminal kinase. Cancer Res 66:445-452